PARP inhibitors Aug 17, 2022 Oncologists Consider Germline Testing in Lung Cancer Patients Amid New Data Showing High Prevalence Premium Aug 4, 2022 Merck, AstraZeneca Net European Approval for Adjuvant Lynparza in BRCA-Mutated Early Breast Cancer Aug 2, 2022 Allarity Scraps Dovitinib Single-Agent Plans in Kidney Cancer, Refocuses on Combination Therapies Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 13, 2022 Oncologists Seeing Lack of PARP Inhibitor Response in MSI-High, BRCA-Mutant Prostate Cancer Patients Apr 12, 2022 Next-Generation AstraZeneca PARP1 Inhibitor Shows Activity in Multiple Cancers at Variety of Doses Apr 11, 2022 UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study Apr 4, 2022 MNM Bioscience Wins $800K Eurostars Grant to Stratify Ovarian Cancer Patients Feb 17, 2022 Mass General, Lunaphore Technologies to Develop Test to Predict PARP Inhibitor Response Feb 7, 2022 Varsity Pharmaceuticals Licenses Pol-Theta Inhibitor From Dana-Farber Cancer Institute Jan 31, 2022 Ideaya Options Exclusive Rights to PARG Inhibitor From CRUK, University of Manchester Jan 3, 2022 Allarity Therapeutics, Oncoheroes Biosciences Ink Pediatric Cancer Licensing Agreement Nov 30, 2021 AstraZeneca, Merck File Adjuvant Lynparza sNDA for Early-Stage Breast Cancer Nov 4, 2021 Repare Therapeutics' RP-3500 Shows Potential of ATR Inhibitors in Precision Oncology Premium Nov 4, 2021 Burning Rock, Impact Therapeutics Ink Testing Deal for ATR Inhibitor Nov 3, 2021 Clovis' Q3 Rubraca Sales Drop 2 Percent Sep 27, 2021 Genetron Health, Impact Therapeutics Partner for Anti-Cancer Drug, CDx Development Sep 15, 2021 KSQ Therapeutics Begins Trial of USP1 Inhibitor for Advanced Solid Tumors Aug 3, 2021 Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib Jun 17, 2021 ASCO Updates Guideline Recommending Adjuvant Lynparza for BRCA1/2-Mutated Early Breast Cancer Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
